A daily regimen of risedronate was found to have superior efficacy to that of intermittent cyclical etidronate in increasing bone mineral density (BMD) among a cohort of Japanese patients with involutional osteoporosis.
Clinicians enrolled 235 patients with involutional osteoporosis in a multi-centre, randomized, double-masked, active (etidronate) controlled comparative trial. The clinical benefit of 2.5 mg daily risedronate and its effects on BMD of the lumbar spine was compared with etidronate, a representative of the bisphosphonates currently marketed in Japan. The patients were randomized to receive either 2.5 mg/day of risedronate for 48 weeks, or intermittent treatment with etidronate in four cycles of two weeks treatment with 200 mg/day, followed by 10 week medication-free periods.
Both treatment groups were given daily 200 mg calcium supplement in the form of the calcium lactate. Bone mineral density of the lumbar spine (L2-L4 BMD) was determined at 12, 24, 36 and 48 weeks by dual-energy X-ray absorptiometry.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!